COMPANY

Ribonova

Keywords: small molecule Mitochondrial Disease Chronic Kidney Disease Probucol

Profile checked Oct 10, 2026

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06931834	Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease	Not listed	Available	Not listed	Not listed

Annual award amounts. Total $1.6M.

2018 NIH contract (government contract; not a grant and not an investment round) 261201800034C-0-0-1 FY2018: $299,438 awarded for that fiscal year; activity N01 (OTHER_NIH); PI WEBB, NIGEL; recipient as written: RIBONOVA, INC., WYNNEWOOD, PA. IGF::OT::IGF Novel ma source ↗
Mar 1, 2017 NIH award 4R44DA042467-02 FY2017: $973,114 awarded for that fiscal year; activity R44 (SBIR); PI WEBB, NIGEL LAWRENCE; recipient as written: RIBONOVA, INC., WYNNEWOOD, PA. Development of novel research tools and a da source ↗
Aug 17, 2016 NIH award 1R42DA042467-01 FY2016: $149,993 awarded for that fiscal year; activity R42 (STTR); PI WEBB, NIGEL LAWRENCE; recipient as written: RIBONOVA, INC., WYNNEWOOD, PA. Development of novel research tools and a da source ↗
Jan 15, 2015 NIH award 1R41DA038970-01 FY2015: $177,206 awarded for that fiscal year; activity R41 (STTR); PI WEBB, NIGEL LAWRENCE; recipient as written: RIBONOVA, INC., WYNNEWOOD, PA. Novel mass spectrometry methods for profilin source ↗